IP Verse

Methods For Evaluating An Immune Response To A Therapeutic Agent - EP3264094

The patent EP3264094 was granted to Biogen MA on Aug 19, 2020. The application was originally filed on Apr 4, 2006 under application number EP17174144A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3264094

BIOGEN MA
Application Number
EP17174144A
Filing Date
Apr 4, 2006
Status
Granted And Under Opposition
Jul 17, 2020
Publication Date
Aug 19, 2020
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

POLPHARMA BIOLOGICSMay 18, 2021WICHMANNADMISSIBLE

Patent Citations (32) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONEP0239400
DESCRIPTIONUS2003070185
DESCRIPTIONUS2003232333
DESCRIPTIONUS3817837
DESCRIPTIONUS3850752
DESCRIPTIONUS3939350
DESCRIPTIONUS3996345
DESCRIPTIONUS4275149
DESCRIPTIONUS4277437
DESCRIPTIONUS4366241
DESCRIPTIONUS4399216
DESCRIPTIONUS4472509
DESCRIPTIONUS4634665
DESCRIPTIONUS4938948
DESCRIPTIONUS5179017
DESCRIPTIONUS5530101
DESCRIPTIONUS5585089
DESCRIPTIONUS5648260
DESCRIPTIONUS5693761
DESCRIPTIONUS5693762
DESCRIPTIONUS5789650
DESCRIPTIONUS5798230
DESCRIPTIONUS5840299
DESCRIPTIONUS5849992
DESCRIPTIONUS5888507
DESCRIPTIONUS6407213
DESCRIPTIONUS6602503
DESCRIPTIONWO9007861
DESCRIPTIONWO9634096
OPPOSITIONWO2006107962
OPPOSITIONWO2007103112
SEARCHWO03016909

Non-Patent Literature (NPL) Citations (44) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
DESCRIPTION- BOERNER ET AL., J. IMMUNOL., (1991), vol. 147, pages 86 - 95
DESCRIPTION- BURTON; WOOF, ADV. IMMUNOL., (1992), vol. 51, pages 1 - 84
DESCRIPTION- Current Protocols in Molecular Biology, JOHN WILEY & SONS, (1989), pages 6.3.1 - 6.3.6
DESCRIPTION- Current Protocols in Molecular Biology, JOHN WILEY & SONS, INC.
DESCRIPTION- GREEN ET AL., NATURE GENETICS, (1994), vol. 7, pages 13 - 21
DESCRIPTION- HEMLER ET AL., J. BIOL. CHEM., (1987), vol. 2, pages 11478 - 11485
DESCRIPTION- HOOGENBOOM ET AL., IMMUNOL TODAY, (2000), vol. 2, pages 371 - 378
DESCRIPTION- HOOGENBOOM ET AL., IMMUNOTECHNOLOGY, (1998), vol. 4, pages 1 - 20
DESCRIPTION- HUANG; STOLLAR, J. IMMUNOL. METHODS, (1991), vol. 141, pages 227 - 236
DESCRIPTION- ISSEKUTZ; WYKRETOWICZ, J. IMMUNOL., (1991), vol. 147, page 109
DESCRIPTION- JEFFERIS ET AL., IMMUNOL. REV., (1998), vol. 163, pages 59 - 76
DESCRIPTION- KAUFMAN; SHARP, MOL. BIOL., (1982), vol. 159, pages 601 - 621
DESCRIPTION- PERSSON ET AL., PROC. NAT. ACAD. SCI. USA, (1991), vol. 88, pages 2432 - 2436
DESCRIPTION- POWERS ET AL., J IMMUNOL METHODS, (2001), vol. 251, pages 123 - 135
DESCRIPTION- PULIDO ET AL., J. BIOL. CHEM., (1991), vol. 266, no. 16, pages 10241 - 10245
DESCRIPTION- QUEEN ET AL., PROC NATL ACAD SCI USA., (198912), vol. 86, no. 24, pages 10029 - 10033
DESCRIPTION- RIECHMANN ET AL., NATURE, (1988), vol. 332, pages 323 - 327
DESCRIPTION- SANCHEZ-MADRID ET AL., EUR. J. IMMUNOL., (1986), vol. 16, pages 1343 - 1349
DESCRIPTION- SHEREMATA ET AL., NEUROLOGY, (1999), vol. 52, page 1072
DESCRIPTION- SHEREMATA ET AL., NEUROLOGY, (1999), vol. 52, pages 1072 - 1074
DESCRIPTION- TEMPEST ET AL., BIOTECHNOLOGY, (1991), vol. 9, pages 266 - 271
DESCRIPTION- URLAUB; CHASIN, PROC. NATL. ACAD. SCI. USA, (1980), vol. 77, pages 4216 - 4220
DESCRIPTION- VAUGHAN ET AL., NAT BIOTECHNOL., (199603), vol. 14, no. 3, pages 309 - 314
DESCRIPTION- VERHOEYEN ET AL., SCIENCE, (1988), vol. 239, pages 1534 - 1536
OPPOSITION- Anonymous, "TYSABRI® (natalizumab) DESCRIPTION", fda, (20050308), pages 1 - 11, XP093039260
OPPOSITION- "Antibody product catalogue", Maine Biotechnology Services Inc., (2015), XP055476851
OPPOSITION- CALABRESI et al., Neurology, (20050300), vol. 64, no. 1
OPPOSITION- "FDA grants accelerated approval of TYSABRI, formerly antegren, for the treatment of MS", EurekAlert, (20041123), XP055809841
OPPOSITION- "HUMAN ANTIGLOBULIN RESPONSES", ROSKOS et al., Measuring Immunity, Lotze & Thomson, (20040000), ISBN 0-12-455900-X, XP008058931
OPPOSITION- KUUS-REICHEL et al., "Will immunogenicity limit the Use, Efficacy and the Future Development of therapeutic monoclonal Antibodies?", Clinical and Diagnostic Laboratory Immunology, (19940000), pages 365 - 372, XP055809845
OPPOSITION- SHEREMATA et al., "A Safety and Pharmacokinetic Study of Intravenous Natalizumab in Patients with MS", Neurology, (19990000), vol. 52, pages 1072 - 1074, XP002997442
OPPOSITION- SUBRAMANYAM M, "Case Study: Immunogenicity of Natalizumab", Biotechnology: Pharmaceutical Aspects, (20080000), pages 173 - 187, XP055476763
OPPOSITION- TUBRIDY et al., "The effect of anti-alpha4 integrin antibody on brain lesion activity in MS", American Academy of Neurology, (19990000), XP008050557
OPPOSITION- RISPENS et al., "Measurement of serum levels of natalizumab, an immunoglobulin G4 therapeutic monoclonal antibody", Anal. Biochem., (20110000), vol. 411, pages 271 - 276, XP028171776
OPPOSITION- MIRE-SLUIS et al., "Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products", Journal of Immunological Methods, (20040000), vol. 289, pages 1 - 16, XP004520874
OPPOSITION- "Natalizumab", nature review, (2005), vol. 4, pages 101 - 102, XP009123651
OPPOSITION- NOSEWORTHY et al., "Natalizumab", Nature Reviews Drug Discovery, (20050200), vol. 4, doi:10.1038/nrd1637, pages 101 - 102, XP009123651
OPPOSITION- CALABRESI et al., "The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL", Neurology, (20070000), vol. 69, pages 1391 - 1403, XP002694856
SEARCH- CALABRESI PETER A ET AL, "Safety and tolerability of natalizumab: Results from the SENTINEL trial", NEUROLOGY, & 57TH ANNUAL MEETING OF THE AMERICAN-ACADEMY-OF-NEUROLOGY; MIAMI BEACH, FL, USA; APRIL 09 -19, 2005, (200503), vol. 64, no. 6, Suppl. 1, ISSN 0028-3878, page A277, XP009073089 [X] 1-12 * abstract *
SEARCH- ENNS R ET AL, "Enact-2 safety, tolerability, and immunogenicity results of natalizumab in patients with Crohn's disease", AMERICAN JOURNAL OF GASTROENTEROLOGY, & 69TH ANNUAL MEETING OF THE AMERICAN-COLLEGE-OF-GASTROENTEROLOGY; ORLANDO, FL, USA; OCTOBER 29 -NOVEMBER 03, 2004, (200410), vol. 99, no. 10, Suppl. S, ISSN 0002-9270, page S269, XP009073091 [I] 1-12 * abstract *
SEARCH[ ] - GASTROENTEROLOGY, DIGESTIVE DISEASE WEEK/105TH ANNUAL MEETING OF THE AMERICAN-GASTROENTEROLOGICAL-ASSOCIATION; NEW ORLEANS, LA, USA; MAY 16 20, 2004, (200404), vol. 126, no. 4, Suppl. 2, ISSN 0016-5085, page A463
SEARCH- ROSKOS L K ET AL, "HUMAN ANTIGLOBULIN RESPONSES", MEASURING IMMUNITY, ELSEVIER,, NL, (200412), pages 172 - 186, XP008058931 [Y] 1-12 * paragraph bridging left- and right-hand columns on page 178; page 178, right-hand column, second paragraph; figure 13.3; page 181, right-hand column, second full paragraph *
SEARCH- SANDS BRUCE E ET AL, "Safety and tolerability of natalizumab in patients concurrently receiving infliximab in a phase 2 study of active Crohn's disease", BIOSIS, BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US, (200404), Database accession no. PREV200600085330, XP002401100 [I] 1-12 * abstract *
SEARCH- BAERT F ET AL, "INFLUENCE OF IMMUNOGENICITY ON THE LONG-TERM EFFICACY OF INFLIXIMAB IN CROHN'S DISEASE", NEW ENGLAND JOURNAL OF MEDICINE, MASSACHUSETTS MEDICAL SOCIETY, BOSTON, MA, US, (20030213), vol. 348, no. 7, ISSN 1533-4406, pages 601 - 608, XP009037271 [Y] 1-12 * abstract; paragraph bridging pages 602 and 603 *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents